U.S. markets close in 2 hours 46 minutes

BiondVax Pharmaceuticals Ltd. (BVXV)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
38.47+0.59 (+1.56%)
As of 1:12PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Fast Stochastic

Fast Stochastic

Previous Close37.88
Open39.30
Bid38.10 x 900
Ask38.48 x 1000
Day's Range38.24 - 42.19
52 Week Range5.20 - 62.00
Volume81,072
Avg. Volume121,725
Market Cap443.198M
Beta (5Y Monthly)2.16
PE Ratio (TTM)N/A
EPS (TTM)-2.30
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est81.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Last of 12,400 Participants Completes Final Visit in BiondVax's M-001 Universal Flu Vaccine Pivotal Phase 3 Clinical Trial
    PR Newswire

    Last of 12,400 Participants Completes Final Visit in BiondVax's M-001 Universal Flu Vaccine Pivotal Phase 3 Clinical Trial

    BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) today announced that all participants in the placebo-controlled, blinded, pivotal, clinical efficacy, Phase 3 trial of BiondVax's M–001 universal influenza vaccine candidate have now completed their site visits. In total, over 12,400 volunteers aged 50+ (with half aged 65+) were enrolled in the trial over the past two flu seasons in 83 sites across seven European countries. The purpose of the study is to assess M-001's ability as a standalone non-adjuvanted vaccine to provide clinical protection from circulating influenza strains as measured by reduction of influenza illness rate (as a primary endpoint) and severity (as a secondary endpoint), as well as to assess M-001's safety.

  • BiondVax Announces First Quarter 2020 Financial Results
    PR Newswire

    BiondVax Announces First Quarter 2020 Financial Results

    BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal influenza vaccine candidate, today announced its first quarter financial results for the quarter ended March 31, 2020.

  • BVXV: Positive Results in NIH-Sponsored Phase 2 Trial of M-001; Raising Valuation to $81…
    Zacks Small Cap Research

    BVXV: Positive Results in NIH-Sponsored Phase 2 Trial of M-001; Raising Valuation to $81…

    By David Bautz, PhD NASDAQ:BVXV READ THE FULL BVXV RESEARCH REPORT Business Update Topline Results from Phase 3 Trial of M-001 Expected by End of 2020 BiondVax Pharmaceuticals, Ltd. (NASDAQ:BVXV) is a biopharmaceutical company developing a universal influenza vaccine (M-001) designed to protect individuals from all strains of influenza. The company’s strategy for commercializing M-001 involves